MX346678B - Sales de arginina utiles inmunologicamente. - Google Patents

Sales de arginina utiles inmunologicamente.

Info

Publication number
MX346678B
MX346678B MX2014010423A MX2014010423A MX346678B MX 346678 B MX346678 B MX 346678B MX 2014010423 A MX2014010423 A MX 2014010423A MX 2014010423 A MX2014010423 A MX 2014010423A MX 346678 B MX346678 B MX 346678B
Authority
MX
Mexico
Prior art keywords
arginine salts
immunologically useful
immunologically
useful
arginine
Prior art date
Application number
MX2014010423A
Other languages
English (en)
Spanish (es)
Other versions
MX2014010423A (es
Inventor
Jain Siddhartha
Kay Dodd Stephanie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014010423A publication Critical patent/MX2014010423A/es
Publication of MX346678B publication Critical patent/MX346678B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2014010423A 2012-03-07 2013-03-07 Sales de arginina utiles inmunologicamente. MX346678B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (2)

Publication Number Publication Date
MX2014010423A MX2014010423A (es) 2014-09-22
MX346678B true MX346678B (es) 2017-03-29

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010423A MX346678B (es) 2012-03-07 2013-03-07 Sales de arginina utiles inmunologicamente.

Country Status (18)

Country Link
US (1) US9320748B2 (https=)
EP (1) EP2822947B1 (https=)
JP (1) JP6325986B2 (https=)
CN (1) CN104203946B (https=)
AU (1) AU2013229466A1 (https=)
CA (1) CA2865759C (https=)
CY (1) CY1118091T1 (https=)
DK (1) DK2822947T3 (https=)
ES (1) ES2597755T3 (https=)
HR (1) HRP20161354T1 (https=)
HU (1) HUE030175T2 (https=)
LT (1) LT2822947T (https=)
MX (1) MX346678B (https=)
PL (1) PL2822947T3 (https=)
PT (1) PT2822947T (https=)
RU (1) RU2014140336A (https=)
SI (1) SI2822947T1 (https=)
WO (1) WO2013131985A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
BE1022857A1 (fr) 2014-03-26 2016-09-27 Glaxosmithkline Biologicals Sa Immunisation contre staphylococcus aureus
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
CA2557353A1 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
EP1891096A2 (en) 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2006341122B2 (en) 2005-12-22 2013-08-22 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
RU2011154363A (ru) 2009-06-01 2013-07-20 Новартис Аг Комбинации клад rrgb пневмококков
CA2765112A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
ES2443952T3 (es) * 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
SG11201400210RA (en) * 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Also Published As

Publication number Publication date
PL2822947T3 (pl) 2017-01-31
HRP20161354T1 (hr) 2016-12-02
AU2013229466A1 (en) 2014-09-04
JP2015511957A (ja) 2015-04-23
CN104203946A (zh) 2014-12-10
HUE030175T2 (en) 2017-04-28
EP2822947A1 (en) 2015-01-14
LT2822947T (lt) 2016-10-10
ES2597755T3 (es) 2017-01-20
CA2865759C (en) 2020-07-21
WO2013131985A1 (en) 2013-09-12
US20150125475A1 (en) 2015-05-07
US9320748B2 (en) 2016-04-26
JP6325986B2 (ja) 2018-05-16
DK2822947T3 (en) 2016-09-19
EP2822947B1 (en) 2016-08-03
CY1118091T1 (el) 2017-06-28
CN104203946B (zh) 2017-03-22
MX2014010423A (es) 2014-09-22
CA2865759A1 (en) 2013-09-12
PT2822947T (pt) 2016-09-26
SI2822947T1 (sl) 2016-10-28
RU2014140336A (ru) 2016-04-27

Similar Documents

Publication Publication Date Title
MX2014010423A (es) Sales de arginina utiles inmunologicamente.
AR117799A2 (es) Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
PT2648520T (pt) Formulação de pré-mistura de dexmedetomidina
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
EP3036226A4 (en) Inhibitors of human 12/15-lipoxygenase
EP3042652A4 (en) Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
IL236965B (en) Derivatives of 5-aminolevulinic acid and uses thereof
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
AU342936S (en) Insole
BR112014000256A2 (pt) formulação de microemulsões transparentes e nutritivas
AU340528S (en) Insole
AU343718S (en) Sticking plaster used for medical purposes
AU343717S (en) Sticking plaster used for medical purposes
IN2015DN00085A (https=)
ZA201306239B (en) Storage-stable formulation of paracetamol in aqueous solution
EP2986112A4 (en) PREPARATION AND USE OF FULVINIC ACID DERIVATIVES
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IN2014DN10658A (https=)

Legal Events

Date Code Title Description
FG Grant or registration